About LGC

Financial results

Financial highlights 2004-2005

These are the first results following Legal & General Ventures' (LGV) replacement of 3i as LGC's private equity investor in April 2004.

Investing in growth

Investment has been focused on growth in the UK, Europe and India with plans in place to expand LGC's operational activity in forensic and pharmaceutical services. During the year, all areas of the business have grown organically and contributed to a record annual turnover of £64m.

Other highlights of the past year include:

Investment in the construction of new laboratories to expand LGC's capability in chemical synthesis (Pharmaceutical & Chemical Services, India) and contact traces (Forensic Services, Runcorn);
Significant developments in outsourcing to LGC with contracts from several multinational companies being delivered from our Runcorn site;
DTI approval for a new three-year Government Chemist programme to support our statutory work as the referee analyst;
LGC's first HyBeacons^® licence agreement with Osmetech plc to use our DNA probe technology to access the medical genetics testing market in the USA;
As one of the UK's National Measurement Institutes, LGC's identification of core measurement issues affecting regenerative medicine and bioprocessing in support of the DTI's new Measurement for Emerging Technologies programme;
The addition to LGC's intellectual property portfolio of a method for the screening of genetic profiles for predisposition to colon cancer;
Winning a joint bid with TUV NEL Ltd to manage the DTI Technology Programme.

Business sector review 2004-05 (1.99MB)

Annual report and accounts 2004-05 (1002.9KB)